Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma

W. Marston Linehan , Paul T. Spellman , Christopher J. Ricketts , W. Marston Linehan , Paul T. Spellman , Christopher J. Ricketts , Chad J. Creighton , Suzanne S. Fei , Caleb Davis , David A. Wheeler , Bradley A. Murray , Laura S. Schmidt , Cathy D. Vocke , Myron Peto , Abu Amar M. Al Mamun , Eve Shinbrot , Anurag Sethi , Samira A. Brooks , W. Kimryn Rathmell , Angela N. Brooks , Katherine A. Hoadley , A. Gordon Robertson , Denise Brooks , Reanne Bowlby , Sara Sadeghi , Hui Shen , Daniel J. Weisenberger , Arnoud Boot , Stephen B. Baylin , Peter W. Laird , Andrew D. Cherniack , Gordon Saksena , Scott M. Haake , Jun Li , Liang Han , Yiling Lu , Gordon B. Mills , Rehan Akbani , Mark D.M. Leiserson , Benjamin J. Raphael , Pavana Anur , Donald P. Bottaro , Laurence Albigès , Nandita Barnabas , Toni K. Choueiri , Bogdan Czerniak , Andrew K. Godwin , A. Ari Hakimi , Thai H. Ho , James J. Hsieh , Michael Ittmann , William Y. Kim , Bhavani Krishnan , Maria J. Merino , Kenna Shaw , Victor E. Reuter , Ed Reznik , Carl Simon Shelley , Hai Hu , Sabina Signoretti , Ramaprasad Srinivasan , Pheroze Tamboli , George Thomas , Satish K. Tickoo , Kenneth Burnett , Daniel Crain , Johanna Gardner , Kevin Lau , David Mallery , Scott Morris , Joseph Paulauskis , Robert Penny , Candace Shelton , W. Troy Shelton , Mark E. Sherman , Eric Thompson , Peggy Yena , Melissa Avedon , Jay Bowen , Julie M. Gastier-Foster , Mark Gerken , Kristen M. Leraas , Tara M. Lichtenberg , Nilsa C. Ramirez , Tracie Santos , Lisa Wise , Erik Zmuda , John A. Demchok , Ina Felau , Carolyn M. Hutter , Margi Sheth , Heidi J. Sofia , Roy Tarnuzzer , Zhining Wang , Liming Yang , Jean C. Zenklusen , Jiashan Zhang , Brenda Ayala , Julien Baboud , Sudha Chudamani , Jia Liu , Laxmi Lolla , Rashi Naresh
2015 New England Journal of Medicine 1,324 citations

Abstract

Type 1 and type 2 papillary renal-cell carcinomas were shown to be clinically and biologically distinct. Alterations in the MET pathway were associated with type 1, and activation of the NRF2-ARE pathway was associated with type 2; CDKN2A loss and CIMP in type 2 conveyed a poor prognosis. Furthermore, type 2 papillary renal-cell carcinoma consisted of at least three subtypes based on molecular and phenotypic features. (Funded by the National Institutes of Health.).

Keywords

Papillary renal cell carcinomasCDKN2ACancer researchClear cell renal cell carcinomaPathologyMedicineRenal cell carcinomaClear cellKidney cancerCancerBiologyInternal medicine

Affiliated Institutions

Related Publications

Publication Info

Year
2015
Type
article
Volume
374
Issue
2
Pages
135-145
Citations
1324
Access
Closed

External Links

Social Impact

Social media, news, blog, policy document mentions

Citation Metrics

1324
OpenAlex

Cite This

W. Marston Linehan, Paul T. Spellman, Christopher J. Ricketts et al. (2015). Comprehensive Molecular Characterization of Papillary Renal-Cell Carcinoma. New England Journal of Medicine , 374 (2) , 135-145. https://doi.org/10.1056/nejmoa1505917

Identifiers

DOI
10.1056/nejmoa1505917